CFGS
CASI

Concourse Financial Group Securities’s CASI Pharmaceuticals CASI Stock Holding History

Concourse Financial Group Securities’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-14
Closed -$393 – 2343
2020
Q4 		$0 Buy
+14
New +$304 ﹤0.01% 2290

Other funds holding CASI

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
IACGFIA
IDG-Accel China Growth Fund III Associates Hong Kong $31.2M AUM 2.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
TLP
Tri Locum Partners New York $813M AUM 101.01% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Concourse Financial Group Securities's CASI Position: Q1 2021 in Review

Concourse Financial Group Securities sold out of CASI Pharmaceuticals (CASI) in Q1 2021, closing a stake of 14 shares — an estimated $393 sold.

Concourse Financial Group Securities first reported a position in CASI in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 85 funds tracked by Wall St. Rank hold CASI as of Q1 2021.

  • Concourse Financial Group Securities reported no remaining CASI Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Concourse Financial Group Securities sold 14 CASI Pharmaceuticals shares in Q1 2021, an estimated $393.
  • Concourse Financial Group Securities first reported a position in CASI Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Concourse Financial Group Securities's CASI Pharmaceuticals position peaked at $0 in Q4 2020.
  • 85 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q1 2021.

Based on Concourse Financial Group Securities's 13F filing for Q1 2021, filed 13 May 2021.